Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register

OBJECTIVES: To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use. METHODS: Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR we...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, Eoghan M, Sutton, Emily, Nesbit, Stephanie, White, James, Parker, Ben, Jayne, David, Griffiths, Bridget, Isenberg, David A, Rahman, Anisur, Gordon, Caroline, D'Cruz, David P, Rhodes, Benjamin, Lanyon, Peter, Vital, Edward M, Yee, Chee-Seng, Edwards, Christopher J, Teh, Lee-Suan, Akil, Mohammed, McHugh, Neil J, Zoma, Asad, Bruce, Ian N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850287/
https://www.ncbi.nlm.nih.gov/pubmed/29216396
http://dx.doi.org/10.1093/rheumatology/kex395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850287/
https://www.ncbi.nlm.nih.gov/pubmed/29216396
http://dx.doi.org/10.1093/rheumatology/kex395

Ejemplares similares